Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization.

Semin Respir Crit Care Med

Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, California 92130, USA.

Published: December 2012

Aspirin-exacerbated respiratory disease (AERD) is a unique syndrome of airway inflammation that frequently occurs in patients with nasal polyposis, chronic sinusitis, and asthma. These patients tend to have progressive and recalcitrant sinus disease requiring frequent surgical intervention and in many cases systemic corticosteroids. Much about the pathogenesis of AERD remains unclear, but environmental factors likely play a prominent role in its development. Avoidance of aspirin or nonsteroidal antiinflammatory drugs (NSAIDs) is imperative in the initial counseling of these patients. Because most of the exposure to these medications is available over the counter, most patients will experience a significant respiratory reaction to full therapeutic doses of seemingly innocent NSAIDs. Although the history of a reaction to aspirin or another NSAID is a very important part of making the diagnosis, the gold standard remains an observed aspirin challenge. Given the prevalence and usefulness of aspirin and NSAID therapy in primary care clinics, an accurate diagnosis should be made in all patients. Desensitization is an effective treatment option for many patients. Recent advances have made this procedure considerably safer and outpatient aspirin desensitization is now the standard of care.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0032-1325618DOI Listing

Publication Analysis

Top Keywords

aspirin-exacerbated respiratory
8
respiratory disease
8
aspirin nsaid
8
patients
6
aspirin
5
disease update
4
update pathogenesis
4
pathogenesis desensitization
4
desensitization aspirin-exacerbated
4
disease aerd
4

Similar Publications

Mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.

Am J Otolaryngol

January 2025

Department of Adult and Development Age Human Pathology "Gaetano Barresi", Unit of Otorhinolaryngology, University of Messina, Via Consolare Valeria 1, 98125 3, Italy. Electronic address:

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation. Mepolizumab was approved for the treatment of CRSwNP in 2021. However, there is a lack of real-life studies.

View Article and Find Full Text PDF

Paradigms and Perspectives: The Evolving Prostaglandin E Story in Chronic Sinus Disease.

J Allergy Clin Immunol

January 2025

Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Jeff and Penny Vinik Center for Translational Immunology Research, Boston, MA, USA 02115.

View Article and Find Full Text PDF

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a recurrent inflammatory disease associated with several comorbidities and a significant disease burden for patients. Treatments include corticosteroids and sinonasal surgery, but these can be associated with the risk of adverse events and nasal polyp recurrence. Biologic treatments such as mepolizumab can be used as an add-on treatment and are effective at reducing surgery and corticosteroid use.

View Article and Find Full Text PDF

Background: Steroid rinses and steroid-eluting stents are both options for preventing postoperative stenosis after frontal sinus surgery. This study aimed to assess whether steroid-eluting stents offer added benefit over steroid rinses alone in postoperative healing and long-term frontal sinus patency.

Methods: A randomized controlled trial enrolled patients with CRS with nasal polyps (CRSwNP) who underwent surgery for bilateral and equal frontal sinusitis after failing prior medical therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!